VGM-R02b Obtained Rare Pediatric Disease Designation (RPDD) from FDA
On May 25, 2022 (Eastern Standard Time), Shanghai Vitalgen BioPharma Co., Ltd. was awarded Rare Pediatric Disease Designation (RPDD) for the drug candidate VGM-R02b in treating glutaric aciduria type I (GA-1) by the Food and Drug Administration (FDA) .